青光眼手術設備的全球市場：增長，趨勢，預測（2020-2025）

Glaucoma Surgery Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: 2022年01月17日 | 出版商:

Mordor Intelligence Pvt Ltd | 英文 117 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全貌
簡介
目錄

簡介

在預測期內，青光眼手術設備的市場規模預計將以6.5％的複合年增長率增長。這是由於青光眼的患病率增加，人口老齡化以及對青光眼採用手術治療的增加。此外，與青光眼有關的微創手術的需求不斷增長，有望推動市場增長。這些療法以諸如更快的手術時間，更快的康復，可負擔性以及更低的併發症風險等優勢帶動市場。根據美國眼科協會（AAO）發佈的報告，全球青光眼的患病率在2013年估計為6430萬，預計到2020年將達到7600萬。此外，有利的報銷政策，政府的積極性以及發展中國家周圍醫療保健的改善有望推動青光眼手術器械市場的發展。

本報告調查了青光眼手術器械的全球市場，提供了市場概況，分析了市場增長和障礙，市場機會以及按產品/手術方法/最終用戶/地區劃分的市場規模趨勢和預測。它提供系統信息，例如競爭狀況和主要公司的概況。

The Glaucoma Surgery Devices Market is expected to register a CAGR of 6.5% during the forecast period. This is attributing to the rising prevalence of glaucoma, increasing geriatric population, growing adoption of surgical treatments for glaucoma. In addition, the rising demand for minimally invasive procedures associated with glaucoma is also expected to trigger the growth of the market. These procedures give benefits like reduced surgery time, faster recovery, affordability, and low risk of complications, thus driving the market. As per the report published by the American Academy of Ophthalmology (AAO), the global prevalence of glaucoma was estimated to 64.3 in 2013 and expected to reach 76 million by 2020. Furthermore, favorable reimbursements policies, rising government initiatives, and improvement in healthcare around developing countries are also expected to boost the glaucoma surgery devices market.

Key Market Trends

Minimal Invasive Glaucoma Surgery by Surgery Type is Estimated to Witness a Healthy Growth in Future.

The minimal invasive glaucoma surgery is expected to witness healthy growth in the future, which is attributed to an increasing number of cataract surgeries and glaucoma surgeries. These devices are extensively used in the surgeries due to their long procedural volume. Moreover, product approvals associated with glaucoma surgery devices are also expected to boost the segment growth. Glaukos Corporation received FDA approval for iStent, a type of minimally invasive glaucoma surgery drainage device used in cataract surgeries. In addition, another company Ivantis also received approval for Hydrus Microstent (MIGS device) I 2018. These devices are efficient in glaucoma surgeries thus results in propelling the segment growth

In addition, the increasing number of glaucoma patients across the world is leading to a high demand for glaucoma surgery devices and thus propelling the overall market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a significant market share in the global Glaucoma Surgery Devices Market due to the increasing prevalence of glaucoma, rising geriatric population, increasing awareness, favorable reimbursements policies, and the presence of several major players. As per a report published by Glaucoma Research Foundation in 2018, an estimate of 3 million people has glaucoma, and the number will be going to increase in the coming years. Moreover, the growing number of geriatric populations in the United States is more prone to have glaucoma. Furthermore, increasing healthcare expenditure and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Glaucoma Surgery Devices Market is moderately competitive and consists of several major players. Some of the companies that are currently dominating the market are Abbott Laboratories Inc, Lumenis, Alcon, Glaukos Corporation, ASICO, LLC., Katalyst Surgical LLC, Allergan, Ziemer Ophthalmic Systems, and Carl Zeiss Meditec.

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support

1 INTRODUCTION

1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Glaucoma
- 4.2.2 Increasing Geriatric Population
- 4.2.3 Growing Adoption of Surgical Treatments for Glaucoma
4.3 Market Restraints
- 4.3.1 Availability of Alternative Treatment Methods
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Product
- 5.1.1 Glaucoma Drainage Device
- 5.1.2 Laser system
- 5.1.3 Punches
- 5.1.4 Probes
- 5.1.5 Others
5.2 By Surgery Method
- 5.2.1 Traditional glaucoma surgery
- 5.2.2 Minimal invasive glaucoma surgery
- 5.2.3 Laser Surgery
5.3 By End User
- 5.3.1 Hospitals
- 5.3.2 Ophtalmic Clinics
- 5.3.3 Others
5.4 Geography
- 5.4.1 North America
  - 5.4.1.1 United States
  - 5.4.1.2 Canada
  - 5.4.1.3 Mexico
- 5.4.2 Europe
  - 5.4.2.1 Germany
  - 5.4.2.2 United Kingdom
  - 5.4.2.3 France
  - 5.4.2.4 Italy
  - 5.4.2.5 Spain
  - 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
  - 5.4.3.1 China
  - 5.4.3.2 Japan
  - 5.4.3.3 India
  - 5.4.3.4 Australia
  - 5.4.3.5 South Korea
  - 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
  - 5.4.4.1 GCC
  - 5.4.4.2 South Africa
  - 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
  - 5.4.5.1 Brazil
  - 5.4.5.2 Argentina
  - 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles
- 6.1.1 Abbott Laboratories Inc
- 6.1.2 Lumenis
- 6.1.3 Alcon
- 6.1.4 Glaukos Corporation
- 6.1.5 ASICO LLC
- 6.1.6 Katalyst Surgical LLC
- 6.1.7 Allergan
- 6.1.8 Ziemer Ophthalmic Systems
- 6.1.9 Carl Zeiss Meditec